At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.
Developing new treatments for cardiometabolic disorders
Non-obstructive hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence in the general population of 1:200.
Stable angina
Chest pain from angina can feel like a heart attack. Stable angina affects more than 4% of the adult population and leads to significant reduction in quality of life.
Heart failure with preserved ejection fraction
Heart failure is a clinical syndrome characterized by the inability of the heart to sufficiently pump blood to meet the body’s metabolic needs.
Pipeline & Technology
Advancing a novel product candidate for cardiac disease
Patients & Physicians
Turning our knowledge of cellular metabolism into new medicines that improve the lives of patients